PTN

Palatin Technologies, Inc.

A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.

Recent Activity

Show $

2013Q2

1 sell

First Eagle Investment ManagementEXIT

-121.1K shares

First Eagle Investment ManagementEXIT

-121.1K shares

2013Q1

1 sell

First Eagle Investment ManagementTRIM

-652.6K shares(-84.3%)

First Eagle Investment ManagementTRIM

-652.6K shares(-84.3%)

Loading more activity...